Along the same lines, recurrence-free survival of TNBC patients was substantially reduced in those individuals with low SLX4IP or high TERT expression (i.e., SLX4IPLow/TERTHigh; Fig 5E), with the opposite expression profile holding similar prognostic value for HER2+ breast cancer patients (i.e., SLX4IPHigh/TERTLow; Fig 5F). This evidence concerns the gene SLX4IP and breast cancer.